

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Schistosomiasis	Thioredoxin glutathione reductase (TGR)	A study in <i>ex vivo</i> parasite samples identified oxadiazole-2-oxide compounds as TGR inhibitors that could help treat schistosomiasis. TGR helps the parasite maintain proper redox balance. In <i>ex vivo</i> samples, 18 different oxadiazole-2-oxide analogs killed 100% of the parasites within 72 hours. Next steps include identifying agents with the best pharmacokinetics and pharmacodynamics for <i>in vivo</i> studies. SciBX 2(38); doi:10.1038/scibx.2009.1443 Published online Oct. 1, 2009	Patent filed covering oxadiazole-2 oxides as antischistosomal agents; available for licensing from the NIH Office of Technology Transfer Contact: Cristina Thalhammer-Reyero, National Institutes of Health, Rockville, Md. phone: 301-435-4507 e-mail: ThalhamC@mail.nih.gov	Rai, G. <i>et al. J. Med. Chem.</i> ; published online Sept. 17, 2009; doi:10.1021/jm901021k Contact: David L. Williams, Rush University Medical Center, Chicago, Ill. e-mail: david_l_williams@rush.edu Contact: Craig J. Thomas, National Cancer Institute, Frederick, Md. e-mail: craig@nhgri.nih.gov